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Abstract
Cisplatin along with other platinum based drugs are some of the most widely used chemotherapeutic agents. However
drug resistance is a major problem for the successful chemotherapeutic treatment of cancer. Current evidence suggests that
drug resistance is a multifactorial problem due to changes in the expression levels and activity of a wide number of proteins.
A majority of the studies to date have quantified mRNA levels between drug resistant and drug sensitive cell lines.
Unfortunately mRNA levels do not always correlate with protein expression levels due to post-transcriptional changes in
protein abundance. Therefore global quantitative proteomics screens are needed to identify the protein targets that are
differentially expressed in drug resistant cell lines. Here we employ a quantitative proteomics technique using stable isotope
labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels
between cisplatin resistant (HeLa/CDDP) and sensitive HeLa cells in an unbiased fashion. A total of 856 proteins were
identified and quantified, with 374 displaying significantly altered expression levels between the cell lines. Expression level
data was then integrated with a network of protein-protein interactions, and biological pathways to obtain a systems level
view of proteome changes which occur with cisplatin resistance. Several of these proteins have been previously implicated
in resistance towards platinum-based and other drugs, while many represent new potential markers or therapeutic targets.
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Introduction
Many current cancer chemotherapy strategies involve disrup-
tion of tumor cell growth by interfering with mitosis or by causing
cancer cells to commit to apoptotic pathways. Cisplatin is a
powerful chemotherapeutic cytotoxin primarily targeting DNA to
form DNA cross-links that can halt cell replication and can
activate a series of signal transduction pathways ultimately leading
to cell death. Acquired and intrinsic resistance to cisplatin
continues to be a major problem for successful clinical treatment
[1]. Generally, acquired resistance is the most common reason for
cancer chemotherapy failure. Possible mechanisms for resistance
to cisplatin include reduced intracellular concentration of cisplatin
by increased drug efflux and/or decreased drug influx, increased
inactivation by reaction with glutathione and other intracellular
nucleophiles, increased repair of DNA damage, and altered
apoptotic signaling pathways [1,2]. Cisplatin along with other
platinum based drugs such as carboplatin and oxiplatin, are seeing
a resurgence of clinical use in combination with other cytotoxic
compounds to treat various carcinomas including ovarian,
colorectal, prostate, lung and breast cancer [3].
Tissue culture studies on drug resistant cell lines generated by
continuous exposure of parental cells to chemotherapeutic
agents have generated much of the current knowledge on the
mechanisms of drug resistance. Genomic microarray experi-
ments are the most commonly applied to study drug resistance
and have successfully identified many genes with altered
expression levels in drug resistant cell lines [4,5]. However the
interpretation of purely transcriptomic data is limited in its ability
to provide a systems level understanding of changes to the
proteome. The proteome is a much more dynamic environment
than the transcriptome due to the kinetics of protein turnover,
post-translational modifications and protein-protein interaction
networks Several studies suggest that quantitative mRNA mea-
surements do not always reflect protein expression levels, likely
due to post-transcriptional changes in protein abundances
[6,7,8,9]. Comparative proteomics studies have also been applied
to the problem of drug resistance in cancer [10]. The majority of
these studies have relied on traditional proteomics techniques
based on quantitative densitometry analysis using two dimen-
sional gel electrophoresis, or Western blotting along with protein
identification by peptide mass fingerprinting. While these
methods generally provide a robust means of profiling changes
in protein expression patterns, identification is labor intensive
requiring that each protein spot of interest be excised and
processed separately. Quantification in gel-based methods is also
challenging due to many factors including overlapping spots,
weak signal intensity, spot positional differences, and mismatched
protein spots.
Proteins function as the mediators of nearly all cellular
processes, either directly or through interactions with other
biomolecules comprising what has been termed the interactome
[11]. Quantitative proteomic expression level data will serve as an
important part of understanding the complex molecular networks
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altered protein expression levels and perturbations to the
interactome will assist in the development of targeted-network
combination therapies with the potential to overcome drug
resistance [12]. However quantitative proteomics data will need
to be integrated with functional biochemical information to reveal
the actual mechanism of drug resistance.
In the present study we have applied an analytical quantitative
proteomics approach employing stable isotope labeling with
amino acids in cell culture (SILAC), to study changes to the
proteome with acquired drug resistance to cisplatin in the HeLa
cervical carcinoma cell line. The cisplatin resistant cell line
HeLa/CDDP was generated previously under exposure to a
clinically relevant concentration of cisplatin (1 mM) and was
found to display a 2.6 fold increase in resistance, compared to
non-resistant HeLa cells, to cisplatin and similar increase in
resistance towards other platinum based drugs [13]. Here we
identify and quantify a total of 856 proteins with 374 proteins
displaying significantly altered abundance levels between the
cisplatin resistant and sensitive cells.
Results
Identification of proteins differentially expressed
between cisplatin resistant and sensitive HeLa cells
Proteomics analysis using SILAC technology was employed to
quantify protein expression level differences between cisplatin
resistant and cisplatin sensitive HeLa cells. A schematic illustrating
the experimental outline is shown in Figure 1. In total we were
able to identify and quantify 1232 proteins, of which 856 were
observed in at least 50% (3/6) of the mixed SILAC samples
(HeLa/CDDP:HeLa mixed at a 1:1 ratio) samples and 50% (3/6)
of the control samples (HeLa/CDDP or HeLa mixed at a 1:1 ratio
with themselves). The average false discovery rate (FDR) for
peptide identification was 0.87%, determined by searching a
randomized decoy database with Mascot. Table S1 displays the
full list of the 856 proteins along with their SILAC ratios.
Histograms illustrating the distribution of relative isotope
abundance (RIA, area of light isotopic distribution divided by
the sum of the areas for the light and heavy isotopic distributions)
values for the control samples and the mixed samples are shown in
Figure 1. Overview of experimental design. HeLa and HeLa/CDDP cells were grown on isotopically light or heavy media. Light and heavy cell
lysates from HeLa and HeLa/CDDP were combined to generate forward and reverse mixed SILAC samples. Light and heavy cell lysates of the same
cell type were combined to generate control samples. Protein samples were reduced, alkylated and digested with trypsin into peptide samples that
were then analyzed by LC-MS/MS. Quantification of SILAC peptide pairs was performed with the software tool, SILACtor. A heat map was used to
visualize proteins displaying increased and decreased expression between HeLa and Hela/CDDP. Finally biological network analysis was combined
with protein expression level data to identify biological pathways relevant to cisplatin resistance.
doi:10.1371/journal.pone.0019892.g001
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broad distribution compared to those from the control samples
indicating that several proteins are differentially expressed in
HeLa/CDDP versus the drug sensitive cells. To determine which
proteins showed altered expression in HeLa/CDDP compared to
HeLa, an analysis of variance (ANOVA) was performed to
compare the mean SILAC ratio for each protein from the mixed
sample type to the control sample type. The resulting F-statistic
and corresponding p-values from the ANOVA are included in
Table S1. In total 387 proteins were found to have significantly
shifted expression levels (p,0.01), of which 184 proteins were
observed with increased expression levels and 203 proteins were
observed with decreased expression levels in HeLa/CDDP. The
184 proteins with increased expression levels had measured RIA
ratios between 0.516 and 0.819 with an average of 0.595,
corresponding to a range from 1.07 to 4.54 fold increase with an
average of 1.54 fold increase in expression levels. The 203 proteins
with decreased expression levels had measured RIA ratios between
0.490 and 0.228 with an average of 0.422, corresponding to a
range from 1.04 to 3.38 fold change with an average of 1.39 fold
decrease in expression levels. Table 1 lists the ten proteins with
the largest increase in expression levels and the ten proteins with
the largest decrease in expression levels. Figure 2B displays the
distributions of RIA values for the proteins identified by ANOVA
with significantly altered expression levels. To further examine the
magnitude of change in protein expression levels that could be
expected to result from normal biological variation, cumulative
distribution analysis was performed on the control samples,
resulting in that a 1.25 fold change or greater (RIA less than
0.444 or RIA greater than 0.556) is not due to biological noise at
the 99% confidence level. A total of 142 proteins from the 184
proteins with increased expression and with ANOVA p-values
,0.01 also exceed the 1.25 fold change cutoff, while a total of 152
proteins from the 203 proteins with decreased expression and p-
Figure 2. Distribution and heat map analysis of quantified proteins. A Histograms illustrating of the distribution of RIA’s observed for the
control samples (blue) and the mixed samples (yellow). B Histogram of the distribution of averaged RIA’s with overlaid distributions of the proteins
identified by ANOVA with significantly decreased ratios (green) and significantly increased ratios (red). Bars are included indicating a61.25 fold
change cutoff which was determined from cumulative distribution analysis of the control sample at the 99% confidence level. C Heat map generated
from SILAC data comparing cisplatin resistant HeLa cells to normal HeLa cells. Lane 1 is light cisplatin resistant and heavy normal cells. Lane 2 is heavy
cisplatin resistant and light normal cells. Lane 3 is a one to one mixture of light and heavy cisplatin resistant cells. Lane 4 is a one to one mixture of
light and heavy normal cells.
doi:10.1371/journal.pone.0019892.g002
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of the observed protein expression level changes is on the same
order as the increased relative resistance of HeLa/CDDP vs.
HeLa to cisplatin (2.6 fold) [13]. Hierarchical clustering of the 856
proteins based on their SILAC ratios was performed to generate a
dendrogram and colored heat map shown in Figure 2C. The
heat map contains four columns corresponding to the two mixed
SILAC samples and two control SILAC samples (column 1-light
HeLa/CDDP:heavy HeLa, column 2-heavy HeLa/CDDP:light
HeLa, column 3- light HeLa/CDDP:heavy HeLa/CDDP,
column 4- light HeLa:heavy HeLa). The heat map image reveals
three general clustered regions which include proteins with
increased expression in HeLa/CDDP, proteins with decreased
expression in HeLa/CDDP, and proteins with unchanged
expression levels. Each lane in the map is an average of three
biological replicates each consisting of technical duplicates. In
general excellent agreement is observed between the inverse mixed
SILAC samples (Figure 2C, columns 1 & 2). A heat map
displaying the signals from each of the biological replicates is
included as Figure S1.
Western Blot
To confirm the differential expression of a few key target
proteins including CD44, DDB-1, DJ-1 and XRCC5, Western
blotting was performed. Levels of b-actin were monitored as a
quantitative control. A cropped version of the Western blot results
with a comparison of the protein ratio calculated from the Western
blot and the SILAC results can be seen in Figure 3. In general
there is good agreement between the two techniques as each of
these proteins was identified with increased expression levels in
HeLa/CDDP compared with normal HeLa. Images of the full
Western blots for each of the selected proteins are included in
Figure S2.
Biological Pathway Analysis of Differentially Expressed
Proteins
The protein interaction network shown in Figure 4 contains
803 proteins and 1174 protein-protein interactions. An interactive
version of this Cytoscape network is provided in Dataset S1.
Several clusters of related functional classes of proteins are visible
in this network including ribosomal proteins, ribonucleoproteins,
Table 1. Proteins with largest increased and decreased expression levels in HeLa/CDDP.
Ten Proteins With Largest Increase in Expression Levels in HeLa/CDDP
UniProt ID Protein Name Change* p-value{ GO Biological Pathway{
ALDR_HUMAN Aldose reductase 4.5460.20 1.73E-03 carbohydrate metabolic process
CATD_HUMAN Cathepsin D 4.4060.03 2.64E-05 autophagic vacuole assembly
G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase 3.9360.03 1.26E-08 NADPH regeneration
S10A4_HUMAN Protein S100-A4 3.7860.03 1.01E-05 positive regulation of I-kappaB
kinase/NF-kappaB cascade
1C05_HUMAN HLA class I histocompatibility antigen, Cw-5
alpha chain
3.1660.06 1.93E-03 immune response
NQO1_HUMAN NAD(P)H dehydrogenase [quinone] 1 2.8960.04 6.50E-07 response to oxidative stress
IDHP_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial 2.8660.03 8.19E-04 2-oxoglutarate metabolic process
CHSP1_HUMAN Calcium-regulated heat stable protein 1 2.8360.02 2.89E-08 intracellular signaling pathway
VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog 2.6960.02 2.74E-04 oxidation reduction
APT_HUMAN Adenine phosphoribosyltransferase 2.6660.03 7.43E-08 adenine metabolic process
Ten Proteins With Largest Decrease in Expression Levels in HeLa/CDDP
UniProt ID Protein Name Change* p-value{ GO Biological Pathway{
H12_HUMAN Histone H1.2 21.8560.05 1.01E-05 nucleosome assembly
NC2A_HUMAN Dr1-associated corepressor 21.9160.05 7.98E-03 negative regulation of
transcription
from RNA polymerase II promoter
PGM1_HUMAN Phosphoglucomutase-1 21.9260.03 6.91E-08 glucose metabolic process
RL1D1_HUMAN Ribosomal L1 domain-containing protein 1 21.9260.14 2.49E-02 RNA processing
BRX1_HUMAN Ribosome biogenesis protein BRX1 homolog 21.9360.02 2.10E-06 ribosome biogenesis
GNAI3_HUMAN Guanine nucleotide-binding protein G(k)
subunit alpha
22.1160.04 1.43E-04 negative regulation of adenylate
cyclase activity
EBP2_HUMAN Probable rRNA-processing protein EBP2 22.2260.06 2.06E-03 ribosome biogenesis
PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein 22.2960.05 9.36E-07 regulation of anti-apoptosis
GBG12_HUMAN Guanine nucleotide-binding protein
G(I)/G(S)/G(O) subunit gamma-12
22.5060.05 5.72E-05 cerebral cortex development
HSB11_HUMAN Heat shock protein beta-11 23.3860.07 1.05E-04 cell adhesion
List of 20 proteins including the ten proteins with largest increased expression levels and ten proteins with the largest decreased expression levels between the cisplatin
resistant and sensitive cells. A complete list with the measured expression levels of the 856 proteins can be seen in Table S1.
*Fold change of protein level measured by SILAC (-) denotes a fold decrease 6 standard deviation.
{p-value determined from ANOVA (p,0.01) considered significant.
{First biological pathway Gene Ontology term associated with protein.
doi:10.1371/journal.pone.0019892.t001
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redox homeostasis and protein folding. To identify the relevant
biological pathways that were altered due to cisplatin resistance,
BiNGO [14] was used to find GO biological pathway and
molecular function terms that were enriched among the
differentially expressed proteins in the network. In total 208
biological pathway terms and 109 molecular function terms were
associated with proteins identified with increased expression, while
101 biological pathway terms and 18 molecular function terms
were associated with proteins identified with decreased expression.
Enriched biological pathways for proteins identified with increased
expression include the metabolism of carbohydrates, metabolism
of NADH and NADPH, regulation of apoptosis, protein folding,
and maintenance of cellular homeostasis. Enriched biological
pathways for proteins identified with decreased expression include
ribosomal assembly and RNA processing, gene expression, and
translation. A complete list of the enriched GO biological pathway
and molecular function terms for the proteins with altered
expression levels can be viewed in Table S2.
Discussion
The combination of quantitative mass spectrometry and
biological network analytical tools allow for a systems-level view
of changes to the proteome that are associated with chemoresis-
tance. Relative expression levels of proteins that carry out key
molecular functions in biological pathways associated with
cisplatin resistance were mapped.
Increased glycolysis and energy producing metabolic
pathways
Several enriched biological pathways from the subset of proteins
identified with increased expression in HeLa/CDDP are related to
glycolysis and carbohydrate metabolism (Figure 5). Thirty
proteins involved in carbohydrate metabolism, including ten
glycolytic and four pentose phosphate pathway enzymes were
measured with increased expression in HeLa/CDDP (Table S2).
Increased glycolytic activity under normal aerobic conditions,
referred to as ‘‘the Warburg effect’’, is a common feature observed
in many malignant cancers and is associated with conditions
including hypoxia, acidosis, and mitochondrial dysfunction [15].
These conditions can lead to enhanced chemoresistance and
malignancy through activation of the hypoxia-induced factor
(HIF) system [15,16]. It was recently shown that HIF-1a confers
chemoresistance by modulating p53 and nuclear factor-kB (NF-kB)
activity [17]. Due to these observations inhibition of glycolysis is
emerging as a potential therapeutic approach for overcoming drug
resistance in cancer [15,18]. Additional enriched metabolic
pathways with enzymes displaying increased expression levels in
HeLa/CDDP includethe TCA cycle,lipid metabolism and NAD
+/
NADP
+ metabolic processes (Figure 5, Table S2). Elevated
production of NADH and NADPH by HeLa/CDDP would help
compensate for the cellular stress and generation of reactive oxygen
species (ROS) due to DNA and protein damage caused by cisplatin
treatment. Aldose reductase (ALDR) had the highest increased
expression levels (4.54 fold) in HeLa/CDDP of any of the proteins
identified in this study (Table 1). Several direct protein interaction
partners of ALDR also had significantly increased levels including
glucose-6-phosphate 1-dehydrogenase (3.93 fold), alpha-aminoadi-
pic semialdehyde dehydrogenase (2.15 fold), transaldolase (1.82
fold), transketolase (1.40 fold), and carbonyl reductase (1.39 fold)
suggesting the related functions and pathways of these enzymes play
an important role in cisplatin resistance. ALDR catalyzes NADPH-
dependent reduction of a wide range of aldehyde containing
compounds to their corresponding alcohols, participating in the
polyol pathway and oxidative stress response. Inhibition of ALDR
activity was shown to enhance chemotherapy sensitivity in HeLa
cells through activation of the extracellular signal-related kinases
(ERK) pathway [19]. Additionally, clinical studies have shown both
overexpression and increased activity of ALDR exist in a number of
human cancer tissues [20].
Redox homeostasis and stress response related proteins
In vivo cisplatin becomes aquated and acts as a potent
electrophile, covalently modifying nucleophilic sites on proteins,
DNA and RNA. The cellular damage caused by cisplatin results in
oxidative stress and formation of ROS, which are important in the
apoptotic mechanism of cisplatin, but have also been implicated in
its nephrotoxic side effects [21,22]. We observed several enriched
pathways and molecular functions related to redox homeostasis
and stress response to be associated with proteins displaying
increased expression in HeLa/CDDP (Figure 5, Table S2).
Increased levels of glutathione (GSH) and proteins in the GSH
system are frequently associated with cisplatin resistance [2,9,13].
Glutathione related enzymes including glutathione transferases
(GSTs) kappa 1 (GSTK1) and omega 1 (GSTO1) were detected
with 1.82 and 1.48 fold increased expression levels respectively in
HeLa/CDDP. Elevated levels of GSTs are generally associated
Figure 3. Western blot analysis. Cropped image of Western blot results comparing levels of four proteins (DDB1, Ku80, CD44, DJ-1) between HeLa
and HeLa/CDDP. ACTB was also monitored as a quantitative control. * The normalized ratio for each protein was calculated by averaging the signal
intensity from three biological replicates from HeLa/CDDP and dividing it by the average signal intensity from 3 biological replicates from HeLa. This
ratio was then normalized using the average ratio of signal intensity of ACTB to the respective protein of interest band. In general there is good
agreement between the ratios obtained from Western blotting and from SILAC. Full Western blot images are available in Figure S2.
doi:10.1371/journal.pone.0019892.g003
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therapeutic targets [23]. In addition to catalyzing the conjugation
of GSH to electrophilic compounds, GSTs also increase resistance
to apoptosis by inhibiting the mitogen activated protein kinase
(MAPK) pathway. Results from a recent study demonstrated that
the overexpression of GSTO1 in HeLa cells confers resistance to
cisplatin primarily through the activation of the phosphatidylino-
sitol-3 kinase/serine/threonine kinase (PI3-K/AKT) pathway and
inhibition of the c-Jun N-terminal kinases (JNK) apoptotic
pathway [24]. We also observed elevated levels of peroxiredoxins,
which are involved in pathways of stress response and regulation of
apoptosis, associated with increased levels in HeLa/CDDP
(Figure 5, Table S2). Peroxiredoxins are antioxidant enzymes
that decompose peroxides and are functionally recycled by
glutathione and GST enzymes. We identified peroxiredoxins 2,
4, 5 and 6 with increased expression levels (1.30, 1.51, 1.60, and
1.29 fold increases respectively) in cisplatin resistant cells.
Overexpression of peroxiredoxins 2 and 6 have been shown to
confer resistance to cisplatin by lowering ROS levels and
inhibiting caspase signaling pathways [25,26].
We also observed several chaperone proteins with significantly
increased expression levels in the cisplatin resistant cells including,
protein disulfide isomerases (PDIA1, PDIA3, PDIA4, PDIA6),
10 kDa heat shock protein, calnexin, peptidyl-prolyl cis-trans
isomerase A, calreticulin, hypoxia up regulated protein 1,
endoplasmin, prefoldin subunit 3, and protein DJ-1. In contrast,
heat shock protein beta-11 was identified with the most decreased
expression levels (23.38 fold) in HeLa/CDDP (Table 1).
Signaling proteins
Protein DJ-1, is an oncogene transcription factor which also
functions in cellular transformation and oxidative stress response.
DJ-1 was identified with increased expression (1.36 fold by SILAC,
3.28 fold by Western blot) in HeLa/CDDP Figure 3. Overex-
pression of protein DJ-1 has been shown to increase cellular
survival by inhibition of JNK pathway and by acting as a negative
regulator of the tumor suppressor phosphatase and tensin homolog
leading to activation of the PI3-K/AKT pathway [27]. Another
study demonstrated DJ-1 exerts cytoprotective action by inhibiting
Bcl-2–associated X protein (Bax) transcription by p53 [28].
Figure 4. Expression level and protein interaction network analysis. Protein interaction network generated with STRING 8.3 [56] and
visualized with Cytoscape [57] consisting of 803 proteins connected by 1174 protein-protein interactions. The 134 proteins with significantly
increased expression levels (p,0.01) of at least 1.25 fold in cisplatin resistant HeLa cells are shown in red. Major clusters of interacting proteins
include those involved in metabolic energy production, protein folding, and cellular signaling. The 147 proteins with significantly decreased
expression levels (p,0.01) of at least 1.25 fold in cisplatin resistant HeLa cells are shown in green. Major clusters of interacting proteins include the
40S and 60S ribosomal proteins and ribonucleoproteins. Interactive Cytoscape networks are included as Dataset S1.
doi:10.1371/journal.pone.0019892.g004
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for the glycosaminoglycan hyaluronan and was identified with
significantly increased levels (1.85 fold by SILAC, 2.21 fold by
Western blot,) in the cisplatin resistant cells (Figure 3). Hyalur-
onan and CD44 have been shown to influence drug resistance
through several mechanisms including cell survival signaling
pathways, drug transporter expression and activity, glycolytic
phenotype, and cancer stem-like cell characteristics [29]. Hyalur-
onan was found to promote CD44 dependent cisplatin resistance
in head and neck cancer [30]. The interaction between
hyaluronan and CD44 has been shown to regulate PI3-K/AKT
signaling and downstream anti-apoptotic events [31]. CD44 is also
one of the most common markers for isolating cancer stem-like
cells, which are a highly malignant subpopulation of cells that
display drug and radiation resistance and have been characterized
in many cancers [29]. Because of these properties it has emerged
as a promising therapeutic target for mitigating the effects of drug
resistance and malignancy in cancer and is currently a prime
therapeutic target for glioblastoma [32]. As Xu et al. show,
upregulation of CD44 may constitute a key event in development
of cancer cell resistance to cellular stresses of a variety of different
origins. CD44 is also a known binding partner of ezrin/radixin/
moesin (ERM) proteins which function to crosslink actin filaments
with plasma membranes [33]. Moesin was identified with 1.41 fold
increased levels in HeLa/CDDP, suggesting that CD44 and its
interacting partner moesin both play an important role in cisplatin
resistance.
The S100 family of proteins consists of small Ca
2+-binding EF-
hand proteins that are known to play a diverse set of roles in many
cancers [34]. In our study S100-P, S100-A4, S100-A6, S100-A11
and S100-A13 were all identified with increased levels (2.48, 3.78,
1.71, 1.86, 1.74 fold increases respectively) associated with
cisplatin resistance. Enriched S100a and S100b binding were
identified in the increased expression GO molecular function
network in Figure 5. S100-A4 and S100-A6 have attracted
significant attention because of their established significance in the
progression of metastatic tumors [35]. Evidence shows S100-A4
inhibits phosphorylation of p53, thereby interfering with its
transcriptional activity and reducing p53 induced apoptosis [36].
Increased gene expression levels of S100-A4 are known to promote
metastasis and have been linked with chemoresistance in
pancreatic and colon cancer cell lines [37,38]. The aspartic
protease, cathepsin D (CATD), was identified with the second
largest increase in expression levels (4.40 fold) Table 1. CATD
Figure 5. Biological pathway and molecular function networks. BiNGO [14] generated biological pathway and molecular function networks
for proteins with significantly altered expression levels associated with cisplatin resistance. Node size is related to the number of proteins associated
with a GO term, while the color relates to the p-value for the statistical significance of the enrichment of a GO term. Interactive Cytoscape networks
are included as Dataset S1.
doi:10.1371/journal.pone.0019892.g005
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important regulator of apoptosis, and promotes invasive and
metastatic properties in tumors [39]. Interestingly CATD has
direct connections with S100-A4, GSTO1, and CD44 in our
protein interaction network (Figure 4), suggesting these interac-
tions could play an important role in apoptotic control in HeLa/
CDDP.
Annexins are another large family of Ca
2+-binding proteins,
fulfilling a wide range of cellular functions including vesicle
trafficking, cell division, apoptosis, and calcium signaling. Several
annexins are also known to interact and form complexes with
S100 proteins (e.g. annexin 1 with S100A11, annexin 2 with
S100A10, and S100A4, and annexin 4 and annexin 11 with
S100A6) [40]. Annexins A2, A4, A5, A6, A7 and A11 were all
detected with increased expression levels in cisplatin resistant
HeLa cells. Increased levels of annexin A4 have been associated
with cisplatin resistance in ovarian cancer and paclitaxel resistance
in the lung cancer cell line H460 [9,41]. Clearly the annexin and
S100 protein families play important roles in cancer biology and
drug resistance making them interesting targets for future studies.
Enrichment of the heme catabolic pathway is observed in
Figure 5 and Table S2, due to increased expression of both
isozymes of biliverdin reductase (biliverdin reductase A, BIEA; and
B, BLVRB) (1.67 and 1.46 fold increase respectively) in HeLa/
CDDP. Overexpression of biliverdin reductase enhances resis-
tance to multiple drugs including cisplatin and doxorubicin,
possibly by mediating protein kinase C activity; however the exact
mechanism of enhanced resistance is unclear [42]. The enzymatic
product, bilirubin is a potent antioxidant and has been shown to
induce expression of multi-drug resistance associated protein and
resistance to cisplatin when added to cultured cells in a conjugated
form [43].
DNA binding and damage repair proteins
While the exact molecular mode of action of cisplatin is not
completely understood, it is clear that DNA is its primary target.
Therefore increased activity of DNA repair mechanisms are
implicated in the resistance to cisplatin [2]. We identified DNA
damage-binding protein 1 (DDB1) and X-ray repair cross-
complementing protein 5 (XRCC5) with significantly increased
expression levels (1.26 and 1.25 fold increases respectively) in the
cisplatin resistant cells. The expression levels of DDB1 and
XRCC5 were also measured by Western blot to be 1.46 fold and
1.11 higher in HeLa/CDDP respectively (Figure 3). However, no
enriched DNA repair pathways were identified indicating that
peripheral functions of these proteins could be important in the
mechanism of cisplatin resistance. In addition to participating in
nucleotide excision repair, DDB1 has been shown to regulate the
cell cycle under conditions of genotoxic stress by targeting the
protein kinase Chk1 to the Cul4 E3-ubiquitin ligase [44].
Similarly, XRCC5 participates in non-homologous end joining
but also suppresses p53-dependent DNA damage response [45].
Interestingly, we identified the DNA-dependent protein kinase
catalytic subunit (PRKDC) with 1.27 fold decreased expression
levels in HeLa/CDDP. PRKDC along with XRCC5 and XRCC6
form the DNA-dependent protein kinase complex (DNA-PK)
which is activated in response to DNA damage and participates in
non-homologous end joining and V(D)J recombination. Tradi-
tionally it has been thought that Ku (a heterodimer of XRCC5
and XRCC6) first binds to the site of DNA damage and recruits
PRKDC to the damaged site to initiate repair. However it has
been shown that PRKDC can be activated in the absence of Ku
[46]. In response to DNA damage, PRKDC has been shown to be
an upstream regulator of p53 induced apoptosis [47]. These results
indicate that lower levels of PRKDC may result in decreased p53
induced apoptosis through the PRKDC regulated pathway in
HeLa/CDDP.
Ribosomal proteins
In our study we detected several ribosomal proteins including 32
proteins of the 60 s ribosomal subunit and 20 proteins of the 40 s
ribosomal subunit, all of which had significantly decreased levels in
the cisplatin resistant cells. Similar results were observed in a
genome microarray study of cisplatin resistant esophageal cancer
cells that found a relatively large number of underexpressed
ribosomal genes to be associated with cisplatin resistance [5]. A
large cluster of ribosomal proteins can be seen in the protein
interaction network in Figure 4B. The consistent under
expression of the ribosomal proteins is interesting in light of
evidence that cisplatin inhibits ribosomal RNA synthesis and
assembly of the ribosomal complex [48,49]. It’s also important to
consider many ribosomal proteins have peripheral functions
related to apoptosis, DNA repair and oncogenesis [5,50].
Therefore decreased levels of these proteins are likely important
factors in the mechanism of cisplatin resistance. Additionally
deregulation of ribosomal transcription could exacerbate the
disparity between mRNA and protein expression levels, which has
been observed with cisplatin resistant cells [9].
Concluding comments
In summary, it is clear that the molecular mechanisms
contributing to cisplatin resistance comprise a complex multifac-
torial network. This study demonstrates that quantitative proteo-
mics analysis using SILAC is a useful technique to identify key
molecular changes which occur with acquired resistance to
cisplatin. Using SILAC we were able to monitor expression levels
for 856 proteins and identify 374 proteins with statistically
significant altered expression levels. Importantly, in contrast to
many drug resistant cell line based studies, these differences were
measured on a drug resistant cell line developed under clinically
relevant levels of cisplatin. These results corroborate known
mechanisms associated with cisplatin resistance and provide new
details on the molecular players involved.
Drug resistance remains a major hurdle for the successful
treatment of cancer. Quantitative proteomic studies such the one
here, are able to identify potential protein targets and cellular
pathways that are altered in the drug resistant phenotype.
However, this type of data really only provides a single snapshot
view of the complete cellular processes involved. It is also
important to consider that in shotgun proteomics experiments
such as the one here, peptides are identified in a data dependent
fashion which results in a bias towards more abundant proteins
and therefore not all proteins in the cell will be measured.
However, as our results show, there are significant differences in
protein expression levels between the cisplatin sensitive and
resistant cells even among the proteins we were able to measure.
In future studies, selected reaction monitoring (SRM) methods can
be used to extend quantitative proteomics studies on drug-resistant
cell lines to proteins with lower expression levels. Ultimately,
integration of protein expression profiling information with studies
probing changes to the dynamics of the proteome and protein-
protein interactions are needed to obtain a more complete view of
perturbations to the interactome. Incorporating interactome data
into the broader context of cellular functional pathways will help
lead to a mechanistic understanding of drug resistance. New
therapeutic strategies based upon such knowledge hold the
promise of individualized treatment with a higher probability of
success.
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15N2 were obtained from
Cambridge Isotope Laboratories (Andover, MA). Dialyzed fetal
bovine serum (FBS) was purchased from PAA Laboratories
(Etobicoke, Ontario). HycloneH penicillin-streptomycin 100x
solution and Pierce Coomassie Plus reagent were purchased from
Thermo Fisher Scientific (Waltham, MA). Antibodies for CD44,
DDB-1, DJ-1 and Ku80 (XRCC5) were purchased from Cell
Signaling Technology (Danvers, MA). Anti-b-actin antibody was
purchased from Sigma (St. Louis, MO). Goat anti-rabbit IRDye
680 and goat anti-mouse IRDye 800 antibodies were supplied by
LI-COR Biosciences (Lincoln, NE). Modified trypsin was
purchased from Promega (Madison, WI). Dulbecco’s Modified
Eagles Medium (DMEM) was custom prepared according to the
formulation by Invitrogen (http://www.invitrogen.com/site/us/
en/home/support/Product-Technical-Resources/media_formulation.
45.html). All other chemicals were reagent or molecular biology grade
and were purchased from Sigma (St. Louis, MO).
Cell Culture
HeLa cells [13] were cultured in DMEM supplemented with
10% FBS and 100 units/mL penicillin-streptomycin, in a
humidified atmosphere containing 5% CO2 at 37uC with media
renewal every 2–3 days. The cisplatin resistant derivative line,
HeLa/CDDP [13], was maintained in identical conditions and
media with the addition of 1 mM cisplatin. For SILAC




15N2 for at least five cell doublings.
Cells were harvested when they reached 80% confluency by
aspirating off the media, washing with ice cold 100 mM
NH4HCO3, then scraped off the dishes and stored at 280uC.
Sample Preparation
Cells were ruptured by repeated rapid freeze/thaw cycles using
liquid N2 and an ultrasonic water bath. The total protein
concentration was determined with the Bradford protein assay.
SILAC samples were prepared by mixing equal amounts of light
or heavy protein from normal HeLa cells with corresponding
heavy or light protein from HeLa/CDDP cells. Control samples
were prepared by mixing equal amounts of light and heavy protein
from the same cell type. Disulfide bonds were reduced with 5 mM
TCEP for 30 minutes, followed by alkylation with 10 mM IAA for
30 min in the dark at room temperature. Protein samples were
digested with a 1:200 ratio of trypsin at 37uC for four hours.
Biological triplicates were prepared for each sample type: light
HeLa/CDDP to heavy HeLa, heavy HeLa/CDDP to light HeLa,
light HeLa/CDDP to heavy HeLa/CDDP, and light HeLa to
heavy HeLa. Samples were stored at 280uC until analyzed by LC-
MS.
Mass Spectrometric Analysis
Peptide samples were loaded onto a trap column (3 cm675 mm
i.d. packed with Michrom Magic C18AQ 200 A ˚ pore size, 5 mm)
and washed for 10 minutes at a flow rate of 2 mL/min with 98%
solvent A (H2O, 0.1% formic acid) and 2% solvent B (acetonitrile,
0.1% formic acid) using a nanoAcquity UPLC (Waters, Milford
MA). Peptides were then fractionated over the analytical column
(30 cm675 mm i.d. packed with Michrom Magic C18AQ 100 A ˚
pore size, 5 mm particles) using a 120 minute linear gradient from
95% solvent A, 5% solvent B to 60% solvent A, 40% solvent B at a
flow rate of 300 nL/min. Peptides were ionized by electrospray
ionization (ESI) using a spray voltage of 2.0 kV. Data dependent
mass spectrometric analysis of SILAC samples was performed
using a LTQ-Orbitrap mass spectrometer (Thermo). Full MS
scans from 400–1400 m/z were performed in the Orbitrap mass
analyzer with the resolution set to 60,000. Tandem mass
spectrometry was performed in the ion trap mass analyzer on
the five most abundant precursors detected in the Orbitrap full
MS scan. Collision induced dissociation was performed using a
normalized collision energy of 35 with a 30 ms activation time and
an activation Q of 0.25. Ions selected for MS/MS sequencing
were then dynamically excluded from repeated MS/MS events for
60 seconds, using an asymmetric mass window of 0.1 m/z on the
low side and 1.1 m/z on the high side. All samples were analyzed
in technical duplicate.
Data Analysis
MS/MS spectra were converted into MGF peak list files using
tools in the Trans-Proteome Pipeline [51] and analyzed using
Mascot v. 2.3 (Matrix Sciences) database searching software [52].
The spectra were searched against the UniProt database (07/07/
10) limited to human taxonomy (20,321 sequences; 11,273,645
residues) with the following search parameters: enzyme set to
trypsin, 25 ppm precursor ion tolerance, 0.8 Da fragment ion




15N2-arginine as variable modifications,
and allowing for a single missed cleavage site. The false discovery
rate (FDR) was determined by searching the MS/MS spectra
against a randomized database. Protein identifications were made
for the highest scoring protein matches to the identified peptides
from Mascot.
Peptide sequences identified with Mascot were exported as
comma separated value (.csv) files using significance and expect
value thresholds of 0.05. This significance level was chosen to give
a FDR of less than 1%. Precursor mass spectra were processed
using Hardklo ¨r [53] to identify peptide isotope distributions and
chromatographic elution profiles. The Hardklo ¨r results and the
.csv files were then analyzed with an in-house developed program,
SILACtor, to label the precursor ions with peptide sequences and
determine the integrated peak areas for each SILAC pair of
isotope distributions. SILACtor provides several useful features not
currently available in other SILAC data analysis software
including; the generation of accurate mass and time target lists
for targeted MS/MS analysis of peptides not identified by the
initial analysis, and the ability to trace and compare SILAC
labeled peptides across multiple time points. The details of
SILACtor will be described in a forthcoming publication, however
in our experience SILACtor demonstrates similar quantitative
performance as MaxQuant [54] as shown in figure S3. SILAC
isotope pairs with mass differences of 6.0201324, 8.0142036,
12.0402648, 14.034336, and 16.0284072 Da were considered,
allowing for the possibility of a single missed tryptic cleavage site
within a peptide sequence which results in the presence of two
isotopically labeled Lys or Arg residues. An accurate mass and
retention time database was constructed consisting of the Mascot
identified peptide sequences with their respective SILAC ratios.
Peptides which were not present in at least 25% of the samples,
had retention times which varied for more than 10 minutes, or
were identified in the wash or equilibration phases of the
chromatography were excluded from the database. Results from
technical replicates for each sample were combined by matching
SILAC pairs with accurate mass (5 ppm) and retention time (5
minutes) and averaging the SILAC ratios across the replicate
analyses. Protein SILAC ratios were obtained by averaging their
constituent peptide SILAC ratios. Average protein SILAC ratios
were obtained by averaging the protein SILAC ratios from
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exceeded twice the standard deviation derived from measurements
on other peptides from the same protein were removed from the
protein analysis and the average protein RIA was re-calculated.
The SILAC RIA values were normalized so that the mean value
for a given sample was 0.5 under the assumption that the majority
of proteins on average will have a 1:1 ratio between the samples.
To determine which proteins had significantly shifted SILAC
ratios between the samples consisting of mixed HeLa/CDDP and
HeLa proteins versus the same cell type mixed with itself a one
way ANOVA was performed using the statistical computing
package R. ANOVA was limited to proteins which were observed
in at least half of the HeLa/CDDP samples and half of the one to
one mixtures of the same cell type samples. Ratios were considered
significantly different if they had a p-value of less than 0.01. To
generate an expression level heat map, SILAC ratios were
analyzed by hierarchical clustering using Gene Cluster 3.0 and
visualized using TreeView [55]. A protein interaction network for
the 856 proteins identified was constructed with STRING 8 [56].
The protein interaction network generated from the STRING
database was visualized with Cytoscape [57]. To obtain enriched
GO biological pathway and molecular function terms related to
cisplatin resistance, BiNGO [14] was used to analyze the proteins
with SILAC ratios that were determined to be significantly
increased or decreased (ANOVA, p,0.01) by at least 1.25 fold in
HeLa/CDDP compared with HeLa. Settings for BiNGO included
using a hypergeometric test with a significance threshold of 0.05.
The Benjamini & Hochberg false discovery rate correction was
applied to the resulting p-values. Proteins were compared against
the full human annotation GO database.
Western Blotting
Cell lysate samples from HeLa and HeLa/CDDP containing
20 mg of total protein were separated by one dimensional SDS-
PAGE using a constant voltage of 100 V. Proteins were
transferred to nitrocellulose membranes using 150 mA constant
current for 2 hrs. Membranes were blocked by incubation for one
hour in PBST (PBS containing 0.1% tween 20) and 5% w/v milk.
Membranes were washed with PBST then incubated for two hours
at room temperature with a 1:1000 dilution of primary antibody
(CD44, DDB-1, DJ-1, or Ku80) and a 1:5000 dilution of anti-b-
actin antibody in PBST containing 5% w/v BSA. Following
extensive washing the membranes were incubated with a 1:20,000
dilution of goat anti-rabbit IRDye 680 and goat anti-mouse IRDye
800 antibodies. Western blots were imaged with a LI-COR
Odyssey infrared imaging system.
Supporting Information
Figure S1 Full heat map image with dendrogram generated
from SILAC ratios for 856 proteins. In total there are 12 lanes
representing 3 biological replicates from 4 sample types. Lanes 1–3
are light HeLa/CDDP, heavy HeLa. Lanes 4–6 are heavy HeLa/
CDDP, light HeLa. Lanes 7–9 are a light and heavy mixture of
HeLa/CDDP. Lanes 10–12 are a light and heavy mixture of
HeLa. The averaged version of this heat map is shown as Figure 3
in the main text for clarity, however the full version allows for the
visualization of the biological replicates.
(PDF)
Figure S2 Western Blot images for four proteins that were
identified by SILAC to have increased levels in cisplatin resistant
HeLa cells. Lanes 1–3 are samples from normal HeLa while lanes
4–6 are from HeLa/CDDP. In each blot b-actin was monitored as
a quantitative control and is visible as a green band at 40 kDa. A
CD44 Western blot with CD44 visible as a green band at 80 kDa.
The averaged ratio of the signal intensity from HeLa/CDDP to
HeLa was 1.31 prior to normalization and 2.21 after normaliza-
tion to the signal intensity from b-actin. B DDB1 Western blot
with DBB1 visible as a red band at 120 kDa. The averaged ratio of
the signal intensity from HeLa/CDDP to HeLa was 1.46 prior to
normalization and 1.13 after normalization to the signal intensity
from b-actin. C DJ-1 Western blot with DJ-1 visible as a red band
at 22 kDa. The averaged ratio of the signal intensity from HeLa/
CDDP to HeLa was 2.75 prior to normalization and 3.28 after
normalization to the signal intensity from b-actin. D XRCC5
(Ku80) Western blot with Ku80 visible as a red band at 85 kDa.
The averaged ratio of the signal intensity from HeLa/CDDP to
HeLa was 1.21 prior to normalization and 1.11 after normaliza-
tion to the signal intensity from b-actin.
(PDF)
Figure S3 Distribution of RIA values for a set of quantified
SILAC peptide pairs from a single control sample, comparing the
quantification results from SILACtor with MaxQuant.
(PDF)
Table S1 Table of 856 proteins identified and quantified.
(XLS)
Table S2 Enriched Gene Ontology Biological Pathway and
Molecular Function Terms for Differentially Expressed Proteins.
(XLS)
Dataset S1 Interactive Cytoscape network.
(TAR)
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